What's on

  • July 25, 2014

    Euroimmun acquires the rights of a patent developed by Dr. Graus and Dr. Dalmau for the diagnosis of autoimmune diseases

    Dr. Graus and Dr. Dalmau have developed a technology for the diagnosis, prognosis and treatment of patients with an autoimmune disease associated to sleep disorders. It is based on detecting the presence of antibodies against the neuronal protein IGLON5 by immunocytochemistry of transfected cells.

    Read the rest of this entry

  • July 18, 2014

    IDIBAPS is the Spanish entity with more activities funded by the Innovative Medicines Initiative

    The report named "Spanish Participation in the Innovative Medicines Initiative (IMI)" has been recently published by the Center for Industrial Technological Development (CDTI). This report lists the main indicators of participation in 8 of the 11 IMI’s calls supported under the 7th Framework Programme.

    Read the rest of this entry

  • July 8, 2014

    IDIBAPS participates in the Graphene Flagship

    In the context of the Graphene Week 2014, the European Commission announced that the Graphene Flagship, one of the largest European research initiatives, is doubling its size and now includes more than 140 organizations from 23 countries. IDIBAPS is one of new 66 partners of the consortium through the team of Maria Victoria Sánchez-Vives, MD, PhD, ICREA Research Professor and team leader of the IDIBAPS group Systems Neuroscience. Professor Sanchez-Vives joins the Neurographene project, coordinated by Rosa Villa, PhD, from the CIBER-BBN Biomonitoring Group at the Barcelona Microelectronics Institute (IMB-CNM), and whose aim is to validate graphene as a brain interface material and to develop devices for both recording neural activity and for brain stimulation. The other partner in this project is the Austrian company Guger Technologies.

    Read the rest of this entry

  • July 3, 2014

    A mutation in progenitor cells identified as origin and therapeutic target for cholangiocarcinoma

    In recent years, cancer research has been focused on the identification of mutations in genes involved in tumor development. Nevertheless, the molecular pathways that contribute to the progression of the disease remain quite unknown. The journal Nature publishes a paper in which an international team of scientists, led by Nabeel Bardesy, PhD, from the Harvard Medical School, suggests that a mutation in the IDH enzyme (isocitrate dehydrogenase), that occurs in liver progenitor cells, promotes the progression of cholangiocarcinoma, a type of liver cancer. Josep M. Llovet, MD, PhD, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York) has collaborated in the study together with Daniela Sia, PhD, and Helena Cornellà, members of the same research group.

    Read the rest of this entry

  • June 26, 2014

    Five researchers from IDIBAPS among the most cited scientists

    Thomson Reuters has published the list of the Highly Cited Researchers, a compilation of the most influential names in science. 50 Spanish researchers from different broad fields of sciences and social sciences appear on the list. In the field of Clinical Medicine, four of the seven Spanish investigators listed are researchers from IDIBAPS. The health research institute associated to Hospital Clínic and Universitat de Barcelona  also has the only Spanish researcher in Psychiatry.

    Read the rest of this entry



  • Monday, 09/29/2014 · IDIBAPS SEMINAR

    Michael A. Gimbrone, Jr., M.D.

    Elsie T. Friedman Professor of Pathology Harvard Medical School Director, Center for Excellence in Vascular Biology, Brigham & Women's Hospital

    Vascular Endothelium: Nature’s Container for Blood— New Insights into its Pathobiology
    Esteve Auditorium IDIBAPS-CEK Building c. Rosselló 149-153, Barcelona

More events